Comparison in curative effects of fondaparinux and low-molecular-weight heparin calcium in treatment of non-ST-segment elevation myocardial infarction
ZHANG Yuan-bo
SHANG Na
ZHOU Rong-bin
LV Su
YANG Meng
SHI Mei-shuang
CHEN Dong-mei
CHEN Xiu-feng
Abstract：Objective To study and compare the curative effects and safety of fondaparinux and low-molecular-weight heparin calcium in treatment of non-ST-segment elevation myocardial infarction (NSTEMI). Methods The patients (n=120) with NSTEMI were chosen from Oct. 2011 to Mar. 2013, and then randomly divided into control group (n=56) and treatment group (n=64). All patients were given retuin therapy to control blood pressure and blood sugar. The control group was then given hypodermic injection of low-molecular-weight heparin calcium (0.1 mL/10 kg) for 7 days and treatment group, fondaparinux (2.5 mg/d) for 7 days. The changes of thrombelastography (TEG) were detected at baseline and after treatment for 2 hours, meanwhile the incidence of major adverse cardiovascular events (MACE, relapse angina, relapse myocardial infarction, death and malignant arrhythmia) and bleeding were observed in two groups. Results There was no significant difference in TEG-R between two groups (P>0.05) both at baseline (4.98 min vs. 5.25 min) and after 2 hours (13.40 min vs. 11.05 min). The incidence of MACE had no statistical difference between two groups during the treatment (7 d:21.43%vs. 6.25%;30 d:21.43%vs. 9.38%;all P>0.05). After treatment for 7 days, the incidence of severe bleeding had no statistical difference between two groups (5.36%vs. 1.56%), while that of mild bleeding decreased significantly in treatment group compared with control group (3.13%vs. 23.21%, P<0.05). After treatment for 30 days, the incidences of severe bleeding (0 vs. 7.14%) and mile bleeding (4.69%vs. 26.79%) decreased significantly in treatment group compared with control group (P<0.05). Conclusion Fondaparinux has the same curative effect and higher safety in the treatment of NSTEMI compared with low-molecular-weight heparin calcium.
Keywords：FondaparinuxLow-molecular-weight heparin calciumNon-ST-segment elevation myocardial infarction
Publication Date：2013-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 363-365 )